BREAKING: On March 17, 2026, the U.S. Food and Drug Administration approved ICOTYDE (icotrokinra), the first oral biologic for the treatment of moderate-to-severe plaque psoriasis. Developed through a partnership between Johnson & Johnson and Protagonist Therapeutics, ICOTYDE represents a seismic shift for the roughly 8 million Americans living with psoriasis — many of whom have avoided or delayed biologic therapy because it required injections.
What Is ICOTYDE?
ICOTYDE is the brand name for icotrokinra, a first-in-class oral peptide that targets the interleukin-23 (IL-23) receptor. IL-23 is a key cytokine driving the inflammatory cascade behind plaque psoriasis. Until now, every IL-23 inhibitor on the market — including Skyrizi (risankizumab), Tremfya (guselkumab), and Ilumya (tildrakizumab) — has been an injectable biologic.
What makes ICOTYDE different is its formulation. Protagonist Therapeutics engineered a constrained cyclic peptide that survives the gastrointestinal tract and retains the potency to block IL-23 signaling from a simple pill. This is not a repurposed small molecule or a JAK inhibitor masquerading as a biologic alternative. It is a genuine oral peptide biologic.
FDA Approval Details
Indication
ICOTYDE is approved for the treatment of moderate-to-severe plaque psoriasis in:
- Adults who are candidates for systemic therapy or phototherapy
- Pediatric patients aged 12 years and older weighing at least 40 kg
Approval Date
March 17, 2026
Manufacturer
Johnson & Johnson (Janssen) in collaboration with Protagonist Therapeutics
How ICOTYDE Works
The IL-23 pathway is central to the development and maintenance of psoriatic plaques. IL-23 activates Th17 cells, which produce downstream inflammatory cytokines like IL-17A and IL-17F. These cytokines stimulate keratinocyte proliferation and the characteristic scaling and redness of plaque psoriasis.
ICOTYDE binds to the IL-23 receptor with high specificity, preventing IL-23 from activating its downstream signaling cascade. Because the drug is a constrained peptide rather than a monoclonal antibody, it can be formulated for oral delivery — a technical achievement that has eluded pharmaceutical developers for decades.
Unlike JAK inhibitors such as Sotyktu (deucravacitinib) or Xeljanz (tofacitinib), which broadly suppress multiple signaling pathways, ICOTYDE is highly targeted. This specificity may translate into a more favorable safety profile, though long-term data will confirm this over time.
Clinical Trial Results
The FDA approval was based on the VIVID phase 3 clinical trial program, which enrolled over 1,800 adults with moderate-to-severe plaque psoriasis.
Key Efficacy Data
| Endpoint | ICOTYDE | Placebo |
|---|---|---|
| PASI 75 at Week 16 | 78% | 6% |
| PASI 90 at Week 16 | 65% | 3% |
| sPGA 0/1 (clear/almost clear) at Week 16 | 65% | 5% |
| PASI 100 at Week 52 | 42% | N/A |
Approximately 65% of patients achieved clear or almost clear skin by week 16, a result that places ICOTYDE in competitive territory with several injectable biologics. By week 52, more than 4 in 10 patients had achieved complete clearance (PASI 100).
How It Compares to Injectable Biologics
| Medication | Type | PASI 90 Rate | Route | Dosing Frequency |
|---|---|---|---|---|
| ICOTYDE | Oral IL-23 inhibitor | ~65% | Oral (daily pill) | Once daily |
| Skyrizi (risankizumab) | Injectable IL-23 inhibitor | ~72–75% | Subcutaneous injection | Every 12 weeks |
| Tremfya (guselkumab) | Injectable IL-23 inhibitor | ~70% | Subcutaneous injection | Every 8 weeks |
| Cosentyx (secukinumab) | Injectable IL-17A inhibitor | ~65% | Subcutaneous injection | Every 4 weeks |
| Humira (adalimumab) | Injectable TNF inhibitor | ~40% | Subcutaneous injection | Every 2 weeks |
| Sotyktu (deucravacitinib) | Oral TYK2 inhibitor | ~37% | Oral (daily pill) | Once daily |
ICOTYDE does not quite match the highest-performing injectables like Skyrizi, but it significantly outperforms Sotyktu and Humira — and it does so without needles. For patients who have been avoiding biologics purely because of injection anxiety, ICOTYDE is a genuine game-changer.
Dosing and Administration
ICOTYDE is taken as a once-daily oral tablet. The recommended dosing schedule includes:
- Induction: 25 mg once daily for the first 4 weeks
- Maintenance: 25 mg once daily thereafter
There is no fasting requirement, no water restriction, and no complex titration schedule. This is a significant practical advantage over oral semaglutide products, which require 30-minute fasting windows.
Side Effects and Safety
In clinical trials, ICOTYDE was generally well tolerated. The most commonly reported adverse events included:
- Upper respiratory infections (8.2% vs 6.1% placebo)
- Headache (4.5% vs 3.8% placebo)
- Diarrhea (3.9% vs 2.4% placebo)
- Nausea (3.1% vs 1.9% placebo)
- Injection site reactions: N/A (oral formulation)
Serious infections were rare and occurred at comparable rates between ICOTYDE and placebo groups. No cases of tuberculosis reactivation or major adverse cardiovascular events (MACE) were reported in the pivotal trials. As with all immunomodulators, patients should be screened for tuberculosis and hepatitis B prior to initiation.
Cost and Insurance Coverage
Johnson & Johnson has not publicly announced an official list price at the time of writing. Based on the pricing of comparable biologics, analysts estimate the wholesale acquisition cost (WAC) will fall in the range of $4,000–$6,000 per month, though manufacturer copay assistance programs are expected to reduce out-of-pocket costs for commercially insured patients to $0–$35 per month.
Medicare Part D coverage is expected but may require prior authorization demonstrating failure of at least one conventional systemic therapy. Patients should work with their dermatologist and pharmacist to verify coverage before filling their first prescription.
Who Should Consider ICOTYDE?
ICOTYDE is best suited for:
- Patients with moderate-to-severe plaque psoriasis who have avoided or refused injectable biologics
- Patients who tried Sotyktu (deucravacitinib) but did not achieve adequate clearance
- Adolescents aged 12+ whose parents prefer an oral medication over injections
- Patients looking for a targeted biologic mechanism (IL-23 blockade) without the broad immunosuppression profile of JAK inhibitors
ICOTYDE is not the right choice for patients who already achieve excellent results on an injectable IL-23 inhibitor like Skyrizi and are comfortable with their current regimen. If the injectable is working and the patient is not injection-averse, switching purely for novelty is not medically indicated.
What This Means for Psoriasis Treatment
The approval of ICOTYDE fills a gap that has frustrated dermatologists for years. The treatment ladder for psoriasis has long had a missing rung: between oral small molecules (methotrexate, Sotyktu, apremilast) with modest efficacy and injectable biologics (Skyrizi, Tremfya, Cosentyx) with excellent efficacy but a needle requirement. ICOTYDE bridges that gap by delivering biologic-class efficacy in oral form.
This approval is also likely to accelerate research into oral peptide biologics for other immune-mediated conditions, including Crohn's disease, ulcerative colitis, and psoriatic arthritis. Protagonist Therapeutics has additional candidates in its pipeline targeting these indications.
The Bottom Line
ICOTYDE is the first oral biologic approved for plaque psoriasis and one of the most significant dermatology approvals in years. With 65% of patients achieving clear or almost clear skin by week 16, it delivers meaningful efficacy without injections. It does not quite match the top-tier injectables on raw clearance rates, but for the large population of patients who have avoided biologics because of needles, ICOTYDE makes biologic-level treatment accessible for the first time.
Talk to your dermatologist about whether ICOTYDE is appropriate for your psoriasis. Use the MedSwitcher comparison tool to see how ICOTYDE compares to your current regimen side-by-side.
Sources
- FDA Press Release: Approval of ICOTYDE (icotrokinra), March 17, 2026.
- Johnson & Johnson press release: ICOTYDE VIVID Phase 3 Results.
- Protagonist Therapeutics pipeline overview, 2026.
- Skyrizi, Tremfya, Cosentyx, Humira, and Sotyktu prescribing information.
- MedSwitcher editorial analysis, April 2026.